NewsRoom Articles - Page 75 of 154 - PsychedelicNewsWire (PNW)

ThursdayDec 16, 2021 1:53 pm

Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) to Conduct Study Investigating Effect of Time on LSD Microdosing

Mind Medicine (NASDAQ: MNMD) (NEO: MMED) (“MindMed”), a psychedelic medicine biotech company, plans to conduct research on how the time of the day during which an individual consumes microdoses of a psychedelic drug impacts the substance’s effects. Microdosing refers to consuming a small dose of a recreational dose of a psychedelic, the most commonly used substances being psilocybin and LSD. The biotech firm announced that its research would focus on assessing and comparing evening and daytime administration of microdoses of LSD. LSD is a psychedelic drug whose effects include intensified emotions, thoughts and sensory perception. For microdoses, small doses are…

WednesdayDec 15, 2021 3:02 pm

Study Opens Door for Future Clinical Trials on Psychedelics for Chronic Pain

Various studies have found that psychedelic substances may be used in the treatment of chronic pain, depression and anxiety, among other indications. Research by Imperial College London looked into the effects of self-medicating psychedelics for the management of chronic pain. While it didn’t evaluate the substances’ effectiveness in treating chronic pain, the study opens the door to different clinical trials that will be carried out in a couple of years. Chronic pain is defined as pain that lasts for more than three months. Estimates show that roughly 20% of the global population lives with chronic pain. Severe and debilitating chronic…

TuesdayDec 14, 2021 3:51 pm

Are Celebrities Helping or Hindering Psychedelics Reform Movement?

The psychedelic renaissance has greatly increased the popularity of psychedelic substances as more research on these substances reveals the numerous benefits they possess. For instance, research has found that psilocybin may be used in the treatment of anxiety while MDMA could be used to manage post-traumatic stress disorder. In the recent past, we have also seen celebrities such as Lil Nas X, Miley Cyrus, Megan Fox and Will Smith speak openly about the use of psychedelics and how the substances have assisted them in overcoming mental health issues. In addition, they revealed how the substances had improved their creative pursuits.…

TuesdayDec 14, 2021 12:37 pm

Meet Delic Sells Out, Becomes World’s Largest Psychedelic Conference

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) held the Meet Delic conference from November 6-7, 2021, in Las Vegas, Nevada The event drew over 2,500 attendees, becoming the largest psychedelic wellness and business conference in the world The event featured over 60 expert speakers and thought leaders, including former NBA champion Lamar Odom and comedian Duncan Trussell Organizers have announced new dates for Meet Delic 2022 in Las Vegas In 2015, famed NBA basketball star Lamar Odom was hospitalized in Las Vegas following a near-death overdose, which resulted in multiple seizures, strokes, and a coma. He would go on to…

MondayDec 13, 2021 2:00 pm

Compass Pathways (NASDAQ: CMPS) Announces Promising Data from Psilocybin Therapy Trial

Recently, Compass Pathways (NASDAQ: CMPS) released new data on its COMP360 psilocybin therapy, which highlights that there’s no evidence suggesting that psilocybin gives rise to serious adverse events. The data also shows that the treatment could provide benefits beyond decreasing depressive symptoms in patients with depression. The psychedelic company’s findings add to data released in November from its phase 2b clinical trial that tested the effectiveness of COMP360 in managing treatment-resistant depression. The trial, which is said to be the biggest psilocybin therapy trial carried out to date, compared two active doses of the therapy — 10 mg and 25 mg…

FridayDec 10, 2021 2:00 pm

DEA Again Bumps Up 2022 Production Quotas for Psychedelics

In a notice that was recently published in the Federal Register, the Drug Enforcement Agency (“DEA”) revised upwards its 2022 quota for the production of illicit controlled substances, such as DMT, MDMA and psilocybin, for research purposes. The agency adjusted its quota once again for these psychedelic substances, in response to the increased demand and interest in the scientific community. When it first released its quota for the year, psilocybin’s production quota was 30 grams. This number has now grown to 8,000 grams, which is more than a 26,000% increase. In its statement, the DEA stated that the aggregate production…

FridayDec 10, 2021 9:32 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) New Patent Application Offering Improved Delivery Control, Enhanced Shelf Stability, of Psilocin

The full patent application covers multiple families of psilocin analogs. Psilocin is the active metabolite of psilocybin In addition to improving delivery control, the company’s dermal application route can potentially eliminate undesirable side effects such as nausea Mydecine appoints Dr. Saeid Babaei, PhD, as an independent board member. The appointment can help advance the company’s NASDAQ listing efforts, bringing decades of experience in biotech development and licensing and strategic advancements Company intends to uplist to NASDAQ in Q1 2022 Improving delivery control and shelf stabilization of psilocybin’s active metabolite psilocin, two critical aspects for use in medical settings, is the…

ThursdayDec 09, 2021 1:36 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Proceed with its Phase 2a Fibromyalgia Study Following FDA Confirmation

Tryp just announced FDA confirmation for its IND application filed in November 2021 The confirmation allows the company to proceed with its Phase 2a study on the effectiveness of psilocybin-assisted therapy among patients with fibromyalgia This clinical study will be one of the first to evaluate synthetic psilocybin for fibromyalgia in a Phase 2 study It is set to commence in 2022 and will involve 20 fibromyalgia patients Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced that it would be proceeding with its upcoming Phase 2a fibromyalgia study, following a confirmation from the U.S. Food and Drug Administration (“FDA”) (https://ibn.fm/C20cT).…

ThursdayDec 09, 2021 1:25 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Fund, Support First-Ever Psychedelic Treatment Clinic at Manhattan Hospital

Company receives grant to fund clinic for marginalized, underserved NYC communities New clinic will offer psychedelic treatment with no out-of-pocket cost for individuals unable to afford the service Program’s clinicians will receive specialized training Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is marking key milestones in its mission to revolutionize mental healthcare. The company recently received a grant for the first-ever psychedelic treatment clinic at Lenox Hill Hospital (https://ibn.fm/zyerA). Part of Northwell Health, the largest healthcare system in New York State, Lenox Hill Hospital serves marginalized and underserved communities on the Upper East…

ThursdayDec 09, 2021 9:25 am

Ongoing Psychedelics Research Could Yield Novel Treatments for Mental Disorders

Data from the National Alliance of Mental Health suggests that one in five adults will suffer from a mental health condition in their lifetime. Traditional treatments cause various side effects and can take time to work, which has prompted researchers to seek alternative treatment options for these conditions. Chang Lu, a researcher from Virginia Tech, has been conducting research on psychedelics that could be used in the treatment of different mental health conditions. Lu, who is a Fred W. Bull Professor of Chemical Engineering, is using a process developed in his laboratory to help collaborators at Virginia Commonwealth University carry…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000